statistiche ricercatore

PASSAMONTI, FRANCESCO

Distribuzione geografica

Continente	#
NA - Nord America	20.301
EU - Europa	9.661
AS - Asia	2.396
SA - Sud America	52
Continente sconosciuto - Info sul continente non disponibili	12
OC - Oceania	7
AF - Africa	6
Totale	32.435

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	20.263
IT - Italia	5.508
UA - Ucraina	1.557
TR - Turchia	997
SE - Svezia	686
IE - Irlanda	613
VN - Vietnam	539
CN - Cina	506
DE - Germania	339
FI - Finlandia	293
GB - Regno Unito	291
SG - Singapore	238
RU - Federazione Russa	184
FR - Francia	63
BR - Brasile	39
JP - Giappone	37
CA - Canada	33
CZ - Repubblica Ceca	29
NL - Olanda	21
HK - Hong Kong	19
ES - Italia	14
BE - Belgio	12
EU - Europa	11
IN - India	10
AT - Austria	8
IR - Iran	8
CL - Cile	7
BG - Bulgaria	6
MY - Malesia	6
SA - Arabia Saudita	6
HU - Ungheria	5
IQ - Iraq	5
NO - Norvegia	5
TW - Taiwan	5
AU - Australia	4
PL - Polonia	4
RS - Serbia	4
TH - Thailandia	4
BD - Bangladesh	3
CH - Svizzera	3
ET - Etiopia	3
GR - Grecia	3
MA - Marocco	3
NZ - Nuova Zelanda	3
RO - Romania	3
AE - Emirati Arabi Uniti	2
AR - Argentina	2
DK - Danimarca	2
IL - Israele	2
LT - Lituania	2
MX - Messico	2
NP - Nepal	2
PE - Perù	2
PK - Pakistan	2
SK - Slovacchia (Repubblica Slovacca)	2
A2 - ???statistics.table.value.countryCode.A2???	1
AL - Albania	1
BA - Bosnia-Erzegovina	1
DO - Repubblica Dominicana	1
EC - Ecuador	1
KR - Corea	1
KZ - Kazakistan	1
LU - Lussemburgo	1
MD - Moldavia	1
NI - Nicaragua	1
OM - Oman	1
PA - Panama	1
PS - Palestinian Territory	1
UZ - Uzbekistan	1
VE - Venezuela	1
Totale	32.435

Salva come PNG Salva come JPEG

Città	#
Milan	4.203
Fairfield	3.290
Woodbridge	2.767
Houston	2.060
Ann Arbor	1.578
Ashburn	1.570
Jacksonville	1.336
Seattle	1.329
Cambridge	1.175
Wilmington	1.122
Chandler	678
Dublin	610
Princeton	525
Dearborn	479
Izmir	473
Nyköping	365
Boardman	330
Dong Ket	271
Rome	235
Singapore	211
San Diego	176
Ogden	133
Como	84
London	80
Redmond	64
Washington	63
Beijing	59
Hefei	50
Kocaeli	48
Nanjing	43
Santa Clara	37
Guangzhou	35
Kunming	35
Kilburn	29
Norwalk	29
Redwood City	25
Brno	24
Düsseldorf	21
Helsinki	21
Tokyo	21
New York	20
Chicago	19
Jinan	19
Zhengzhou	19
Nanchang	18
Toronto	17
Verona	16
San Francisco	15
Acton	14
Changsha	14
Frankfurt am Main	14
Hong Kong	14
Munich	14
Brussels	12
Shenyang	12
Baotou	11
Chiswick	11
Dallas	11
Los Angeles	11
Reston	11
Chengdu	10
Fuzhou	10
Falls Church	9
Hebei	9
Hounslow	9
Prescot	9
Collegeville	8
Florence	8
São Paulo	8
Catania	7
Hangzhou	7
Indiana	7
Quzhou	7
Shanghai	7
Southwark	7
Wandsworth	7
Fayetteville	6
Islington	6
Oxford	6
San Mateo	6
Wuhan	6
Berlin	5
Lachine	5
Memphis	5
Napoli	5
New Bedfont	5
Phoenix	5
San Jose	5
Sapporo	5
Shaoxing	5
Taiyuan	5
Vienna	5
Wenzhou	5
Amsterdam	4
Chongqing	4
Jinhua	4
Madrid	4
Missaglia	4
Ponte Lambro	4
Sesto Fiorentino	4
Totale	26.223

Salva come PNG Salva come JPEG

Nome	#
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm	258
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.	223
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence	219
Analysis of three screening methods for the detection of calreticulin gene mutations	211
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations	209
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group	200
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group	194
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts	187
Mutations and thrombosis in essential thrombocythemia: Prognostic interaction with age and thrombosis history	187
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN	184
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia.	183
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.	181
Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies	181
New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma	179
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis	178
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study	177
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients	176
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.	175
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.	174
Looking for CALR mutations in familial myeloproliferative neoplasms	174
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera	172
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera.	171
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia	171
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT.	170
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.	170
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.	169
Mutational status of myeloproliferative neoplasms.	168
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms	168
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis	168
European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.	166
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms.	165
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis	165
Novel agents in indolent lymphomas	164
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients	164
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms	164
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis	164
Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma	162
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.	162
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early /prefibrotic primary myelofibrosis.	161
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2	161
RBC-transfusion guidelines update	159
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia	159
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients	159
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders	156
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.	156
Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden	156
European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis: Haematologica 2012;97(3):360-5 - Comment	156
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.	155
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients.	155
What are RBC-transfusion-dependence and -independence?	155
Myeloproliferative Neoplasms	155
Disease anticipation in familial myeloproliferative neoplasms.	155
Direct-Acting Antivirals During or After Immunochemotherapy in Hepatitis C Virus-Positive Diffuse Large B-Cell Lymphomas	155
JAK inhibitor in CALR-mutant myelofibrosis	154
Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.	154
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial	154
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons	153
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report	152
How I treat polycythemia vera	152
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project	152
Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia	151
TREATMENT OF POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA: THE ROLE OF PIPOBROMAN.	151
A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion	151
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs	151
New generation small-molecule inhibitors in myeloproliferative neoplasms	150
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy	150
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis	150
Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies	150
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs	150
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients	150
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.	149
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis	149
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.	148
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project	148
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis	148
Cardiovascular events and intensity of treatment in polycythemia vera	147
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)	147
It is time to change thrombosis risk assessment for PV and ET?	146
ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA	146
Standard care and investigational drugs in the treatment of myelofibrosis	146
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia	145
Exaggerated insect bite-like reaction in patients affected by oncohaematological diseases	145
Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper	144
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases	143
A novel germline JAK2 mutation in familial myeloproliferative neoplasms	143
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)	143
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment	143
Blast phase of essential thrombocythemia: A single center study.	143
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders	143
Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations.	143
Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma	143
Developments in diagnosis and treatment of essential thrombocythemia	143
Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection	143
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm	142
Leukemia risk models in primary myelofibrosis: an International Working Group study.	142
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders	141
A gain-of-function mutation of JAK2 in myeloproliferative disorders	141
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study	141
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group	141
Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients	141
Totale	16.108

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	127.811
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	127.811

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2019/2020	4.030	0	0	0	0	0	777	983	805	568	415	126	356
2020/2021	5.671	118	475	541	816	422	540	333	419	645	298	438	626
2021/2022	2.587	335	436	24	118	96	128	150	159	146	416	243	336
2022/2023	2.444	283	79	141	230	177	650	15	300	372	82	40	75
2023/2024	6.571	1.015	1.045	1.030	1.308	1.278	449	66	83	201	20	24	52
2024/2025	1.096	26	12	606	106	104	242	0	0	0	0	0	0
Totale													32.964